CY1108753T1 - Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη - Google Patents

Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη

Info

Publication number
CY1108753T1
CY1108753T1 CY20091100063T CY091100063T CY1108753T1 CY 1108753 T1 CY1108753 T1 CY 1108753T1 CY 20091100063 T CY20091100063 T CY 20091100063T CY 091100063 T CY091100063 T CY 091100063T CY 1108753 T1 CY1108753 T1 CY 1108753T1
Authority
CY
Cyprus
Prior art keywords
cyclude
dextrin
pharmaceutical form
form spray
includes hydro
Prior art date
Application number
CY20091100063T
Other languages
English (en)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1108753T1 publication Critical patent/CY1108753T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Νέες Φαρμακοτεχνικές Μορφές Μερικώς και πλήρως ακυλιωμένων κυκλοδεξτρινών βρέθηκαν ότι είναι διαλυτές σε προωθητικά HFA, και συνεπώς μπορούν να χρησιμοποιηθούν για να τυποποιηθούν σταθερές pMDIs HFA και ως εναιωρήματα και ως διαλύματα.
CY20091100063T 2003-11-26 2009-01-19 Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη CY1108753T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
EP04798662A EP1708679B1 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
CY1108753T1 true CY1108753T1 (el) 2014-04-09

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100063T CY1108753T1 (el) 2003-11-26 2009-01-19 Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη

Country Status (24)

Country Link
US (1) US20070104652A1 (el)
EP (1) EP1708679B1 (el)
JP (1) JP4950666B2 (el)
KR (1) KR20060118509A (el)
CN (1) CN100592908C (el)
AT (1) ATE413868T1 (el)
AU (1) AU2004294775B2 (el)
BR (1) BRPI0416992A (el)
CA (1) CA2546441C (el)
CY (1) CY1108753T1 (el)
DE (1) DE602004017783D1 (el)
DK (1) DK1708679T3 (el)
ES (1) ES2314469T3 (el)
HK (1) HK1108390A1 (el)
IL (1) IL175659A (el)
MX (1) MXPA06005643A (el)
NO (1) NO20062969L (el)
NZ (1) NZ547355A (el)
PL (1) PL1708679T3 (el)
PT (1) PT1708679E (el)
SE (1) SE0303179D0 (el)
SI (1) SI1708679T1 (el)
WO (1) WO2005053637A2 (el)
ZA (1) ZA200604330B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
CN118401627A (zh) * 2021-12-28 2024-07-26 琳得科株式会社 有机硅类粘着剂、粘着片及双面粘着片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW224942B (el) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
PL1708679T3 (pl) 2009-04-30
WO2005053637A3 (en) 2007-06-28
DK1708679T3 (da) 2009-02-16
KR20060118509A (ko) 2006-11-23
NZ547355A (en) 2009-05-31
ZA200604330B (en) 2007-11-28
AU2004294775A1 (en) 2005-06-16
MXPA06005643A (es) 2006-08-17
AU2004294775B2 (en) 2007-12-20
NO20062969L (no) 2006-08-25
JP4950666B2 (ja) 2012-06-13
US20070104652A1 (en) 2007-05-10
IL175659A0 (en) 2006-09-05
IL175659A (en) 2010-02-17
BRPI0416992A (pt) 2007-02-06
DE602004017783D1 (de) 2008-12-24
ES2314469T3 (es) 2009-03-16
CN100592908C (zh) 2010-03-03
EP1708679A2 (en) 2006-10-11
EP1708679B1 (en) 2008-11-12
JP2007515401A (ja) 2007-06-14
ATE413868T1 (de) 2008-11-15
CA2546441C (en) 2011-11-22
HK1108390A1 (en) 2008-05-09
CA2546441A1 (en) 2005-06-16
WO2005053637A2 (en) 2005-06-16
PT1708679E (pt) 2008-12-29
SE0303179D0 (sv) 2003-11-26
SI1708679T1 (sl) 2009-04-30
CN101087600A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
CY2015033I1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
ATE496064T1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
HRP20060240T3 (en) Intranasal formulation of rotigotine
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
WO2001058412A3 (de) Extrakte von rückständen aus der weinherstellung
TW200710220A (en) Foamable alcohol compositions, systems and methods of use
TW200700059A (en) A topical composition and its uses
TW200519105A (en) Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
SE0102438D0 (sv) New compounds
NO20032788D0 (no) Modafinil-forbindelse og cyklodekstrinblandinger
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
AU2003255621A1 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
WO2003066597A3 (en) Guanidino compounds
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
WO2005110421A3 (de) Aerosolformulierung für die inhalation von betaagonisten
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
WO2003063824A3 (en) Pharmaceutical composition
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
FR2885910A1 (fr) Composition aqueuse de nettoyage pour le traitement du cuivre de semi-conducteurs
CY1108753T1 (el) Φαρμακοτεχνικη μορφη σπρει που περιλαμβανει υδρο φθορο αλκανιο και μια ακυλιωμενη κυκλοδεξτρινη
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.